299 related articles for article (PubMed ID: 28946961)
21. Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: A case report.
Kitamura F; Yamaguchi M; Nishimura M; Katsuno T; Ito M; Sugiyama H; Iwagaitsu S; Nobata H; Kinashi H; Ishimoto T; Banno S; Ito Y
Mod Rheumatol Case Rep; 2022 Jun; 6(2):254-259. PubMed ID: 35425980
[TBL] [Abstract][Full Text] [Related]
22. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
23. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies?
Yıldız S; Demirkan F
Transfus Apher Sci; 2018 Feb; 57(1):31-34. PubMed ID: 29506907
[TBL] [Abstract][Full Text] [Related]
24. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome.
Geethakumari PR; Mille P; Gulati R; Nagalla S
Transfus Apher Sci; 2017 Jun; 56(3):400-403. PubMed ID: 28428030
[TBL] [Abstract][Full Text] [Related]
25. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
Dhakal P; Bhatt VR
Bone Marrow Transplant; 2017 Mar; 52(3):352-356. PubMed ID: 27775697
[TBL] [Abstract][Full Text] [Related]
26. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.
Bjørkto MH; Barratt-Due A; Nordøy I; Dörje C; Galteland E; Lind A; Hilli A; Aukrust P; Mjøen G
BMC Infect Dis; 2021 Feb; 21(1):137. PubMed ID: 33526010
[TBL] [Abstract][Full Text] [Related]
27. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
Sengul Samanci N; Ayer M; Ergen A; Ozturk S
Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
[TBL] [Abstract][Full Text] [Related]
28. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
29. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
[TBL] [Abstract][Full Text] [Related]
30. Thrombotic microangiopathy: new insights.
Benz K; Amann K
Curr Opin Nephrol Hypertens; 2010 May; 19(3):242-7. PubMed ID: 20186056
[TBL] [Abstract][Full Text] [Related]
31. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
Demircioglu S; Dogan A; Demir C
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
[TBL] [Abstract][Full Text] [Related]
32. Complement activation and effect of eculizumab in scleroderma renal crisis.
Devresse A; Aydin S; Le Quintrec M; Demoulin N; Stordeur P; Lambert C; Gastoldi S; Pirson Y; Jadoul M; Morelle J
Medicine (Baltimore); 2016 Jul; 95(30):e4459. PubMed ID: 27472742
[TBL] [Abstract][Full Text] [Related]
33. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
[TBL] [Abstract][Full Text] [Related]
34. Complement in the Pathophysiology of the Antiphospholipid Syndrome.
Chaturvedi S; Brodsky RA; McCrae KR
Front Immunol; 2019; 10():449. PubMed ID: 30923524
[TBL] [Abstract][Full Text] [Related]
35. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition.
Sakamoto K; Imamura T; Osone S; Nishimura A; Nishida M; Ishida H; Hosoi H
Pediatr Transplant; 2015 Jun; 19(4):E97-100. PubMed ID: 25735190
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic complement inhibition – from experimental to clinical medicine.
Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
[TBL] [Abstract][Full Text] [Related]
38. Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?
Fakhouri F; Frémeaux-Bacchi V
Nat Rev Nephrol; 2013 Sep; 9(9):495-6. PubMed ID: 23917793
[No Abstract] [Full Text] [Related]
39. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
40. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.
Gloude NJ; Dandoy CE; Davies SM; Myers KC; Jordan MB; Marsh RA; Kumar A; Bleesing J; Teusink-Cross A; Jodele S
J Clin Immunol; 2020 Jul; 40(5):699-707. PubMed ID: 32447592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
